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Objectives:
 
 This paper examines three processes: SSRI
antidepressant choice, adherence to treatment guide-
lines, and long-term health care expenditures associated
with antidepressant treatment for patients with a diag-
nosis of depression.
 
Methods:
 
 Patient records were abstracted from a medi-
cal claims database covering employer-provided health
care plans. Treatment episodes required a 6-month an-
tidepressant-free prior period; initial treatment with
sertraline, paroxetine or fluoxetine; and data on direct
medical costs over the 24 months following the initial
prescription. The multivariate model of drug selection,
patient adherence to antidepressant use guidelines, and
cost was subjected to specification testing to rule out
the possibility that nonrandom initial antidepressant se-
lection might lead to sample selection bias. Further tests
indicated that the results were free of bias due to a pos-
sible correlation between antidepressant selection and
use of the medication, or because of the endogeneity of
use patterns in the process driving cost. However, there
was evidence of unobserved variables correlated with
both achieving guideline adherent use and expendi-
tures, which might have led to sample selection bias.
 
Results:
 
 Subjects who met the study criteria included
796 initiating therapy with sertraline, 352 with parox-
etine, and 882 with fluoxetine. Fluoxetine patients were
significantly more likely than sertraline or paroxetine
patients to achieve a use pattern that was consistent
 
with guidelines for treating depressive disorder (
 
p
 
 
 

 
.05). There were no statistically significant differences
between the three treatment cohorts in total direct
health care expenditures over the 2-year period (
 
p
 
 
 

 
.05), and depression-related expenditures, other mental
health expenditures, and non-mental health care expen-
ditures did not show significant differences across the
treatments (
 
p
 
 
 

 
 .05). Natural logged values of antide-
pressant drug expenditures were predicted to be highest
for fluoxetine, followed by sertraline, then paroxetine
(
 
p
 
 
 

 
 .01). Predicted log values of mental health expen-
ditures were lower for sertraline relative to fluoxetine.
 
Conclusions:
 
 Fluoxetine patients had the highest likeli-
hood of using antidepressant medication according to
treatment guidelines that were developed to assure
quality care. This benefit was achieved without incur-
ring greater total health care expenditures.
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Introduction
 
Recent concern about rising health care expendi-
tures for pharmaceuticals has focused attention on
the cost-effectiveness of prescription medications.
Per-patient expenditures on pharmaceuticals over
a course of treatment are a function of the price of
the product and the amount used. All else being
equal, pharmaceutical expenditures will be greater
for a treatment that a patient uses consistently
over a relatively long period compared to expendi-
tures for a low-priced therapy that is taken only
sporadically or for a short period of time. On the
other hand, the utilization of an effective pharma-
ceutical treatment may favorably influence clinical
outcomes and reduce the overall use of medical re-
sources. Thus, a complete analysis of the impact
of pharmaceutical use on costs of treatment
should include both the direct effect of pharma-
ceutical expenditures and the indirect effect from
potential cost offsets.
Recognition of the clinical and economic im-
portance of appropriate pharmaceutical use led to
the creation of treatment guidelines by health au-
thorities or professional societies for a large num-
ber of acute and chronic conditions. In the case of
medication treatment for depressive disorder, rec-
ommendations often call for at least 6 months of
therapy beyond the point of symptom resolution
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[1]. Guidelines from the United States call for
most patients to receive the full therapeutic dose
of an antidepressant for 4 to 9 months of continu-
ation therapy after symptom remission is achieved
[2]. Switching to a new medication or augmenting
the initial drug selection is not advised until suffi-
cient time has elapsed for an adequate trial of the
initial antidepressant [2]. Retrospective analysis of
adherence to treatment guidelines has documented
that patients in clinical practice who discontinued
antidepressant therapy early were most likely to
experience relapse or recurrence of a depressive
episode 3].
The development of guidelines for measure-
ment of costs in economic evaluations of pharma-
ceuticals has not been finalized although there is
agreement that the costs included depend upon the
perspective taken in the analysis. For questions of
public policy, a societal perspective encompassing
medical and nonmedical costs should be taken. Al-
ternatively, total medical expenditures are the rel-
evant metric for insurers, managed care organiza-
tions (MCO) and other payers. Policies that seek
to minimize antidepressant acquisition costs im-
plicitly assume equal effectiveness of the medica-
tions although differences in drug use patterns
may lead to differential effectiveness in clinical
practice [4,5]. In fact, on an acquisition cost basis,
drugs that are inexpensive, ineffective and have se-
rious side-effect profiles that cause early discontin-
uation of therapy will appear to be less costly than
higher-priced but effective medications. As noted
by the Consensus Committee from the British As-
sociation for Psychopharmacology, “ . . . it is a
false economy to prescribe cheaper drugs with
more side effects that are likely to lead to patients
stopping treatment and the illness being prolonged”
[6]. Studies that include only mental health costs
suffer from the same general criticism, although to
a lesser degree.
Several studies have found that total direct health
care expenditures for patients initiating therapy on
selective serotonin reuptake inhibitors (SSRIs) are
not significantly different from expenditures for
patients who initiate therapy on tricyclic antide-
pressants (TCAs) [7–15]. That is, the higher drug
acquisition costs typically found in the United States
for SSRIs relative to TCAs are offset by lower ex-
penditures for health care services other than anti-
depressant therapy. In contrast, cost comparisons
among the SSRIs have yielded mixed results. Some
studies have indicated that total health care expen-
ditures [10,11] or depression-related expenditures
[16–18] may differ among the SSRIs, while others
report no significant differences in direct total costs
of treatment with fluoxetine, paroxetine, and ser-
traline [19].
The purpose of this paper is to examine the long-
term, direct health care expenditures associated
with episodes of antidepressant therapy. A retro-
spective database analysis of patients with a di-
agnosis of depression in US employer-paid health
care plans compares the influence of treatment
with fluoxetine, sertraline, and paroxetine on direct
health care expenditures over the 2 years following
initiation of the medication. To our knowledge,
this is the first retrospective analysis of long-term
expenditures associated with treatment of depres-
sion. The analysis consists of a specification of the
episode of care that begins with the choice of an
initial antidepressant, extends to the patient’s use
of the medication relative to treatment guidelines,
and evaluates costs during the following 2-year
period. A noteworthy feature of the analysis is the
extensive testing of the model’s specification. The
effort involved in searching for the appropriate
model specification concerns both the limitations
of retrospective data (e.g., omitted variables, selec-
tion bias, measurement error) as well as the com-
plexity of the treatment process and its link to
clinical outcomes. In a technical sense, these com-
plexities reveal themselves as correlation of error
terms across equations and with the variables in
the models. If present, these correlations would re-
sult in biased parameter estimates for the factors
influencing initial antidepressant selection, adher-
ence to treatment guidelines, and health care ex-
penditures.
 
Methods
 
This paper presents a retrospective analysis of the
process of care for depressive disorders. The ana-
lytic file used in this study was constructed from
the 1993 to 1996 panels of the MarketScan (Ann
Arbor, Michigan) database, a system of compre-
hensive and standardized medical and prescription
claims from large employer health care plans across
the United States. The MarketScan database is de-
rived from the pooled inpatient, outpatient, and
pharmacy claims of more than 200 health plans and
administrators. To enhance the quality of the infor-
mation for research purposes, rigorous techniques
for standardizing and integrating the data are ap-
plied. For instance, MarketScan data represent fully
adjudicated claims. Furthermore, financial fields are
standardized across carriers, synthetic identifiers are
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constructed to enable the tracking of individuals
across years while ensuring patient confidentiality,
plan-type identifiers (preferred provider organiza-
tions, point of service, comprehensive, and health
maintenance organizations) are constructed for
each enrollee, and the data are put through a large
number of edit checks in the database construc-
tion process.
Intent-to-treat (ITT) analysis of antidepressant
therapy was followed wherein cohorts were de-
fined according to the type of treatment intended
at the beginning of an episode of care. Although
patients were not randomized to treatment and,
hence, the possibility for selection bias must be ad-
dressed, the fundamental idea behind ITT is to re-
duce bias that might be introduced by excluding
patients who did not complete the originally as-
signed course of therapy from analysis [20]. For
instance, there might have been differential rates
at which patients failed to complete the original
therapy, which could have induced bias favoring
one treatment over another.
Episodes of antidepressant treatment were con-
structed to compare patients across the SSRIs with a
common starting point. A patient’s index date is de-
termined by the date on which the first prescription
for fluoxetine, paroxetine, or sertraline was filled.
Patients are required to have a depression-related di-
agnosis within 30 days of the index date to be in-
cluded in the study. Depression diagnoses included:
Major Depressive Disorder (MDD) single episode;
MDD recurrent episode; Neurotic Depression; Brief
Depressive Reaction; Prolonged Depressive Reac-
tion; and Depressive Disorder Not Elsewhere Clas-
sified (NEC). The inclusion of these diagnoses and
drawing of the sample from a population of out-
patients in primary care or psychiatry settings re-
flects the primary purpose of the manuscript, which
is to examine the 2-year costs of antidepressant
treatments as they are used in clinical practice. A
6-month, antidepressant-free prior period is also re-
quired to ensure that antidepressant use is not part
of an earlier episode, i.e., the index date marks a
new episode of depression treatment. All patients
are followed for 24 months after the index date.
This 2-year interval constitutes the study period.
Data are sufficient to ensure that patients were con-
tinuously enrolled in the plan over the entire 30-
month period. Exclusion criteria include: receipt of
a prescription for lithium or an antipsychotic drug
during the prior or study periods; a diagnosis of bi-
polar disorder, schizophrenia, any psychotic disor-
der, or substance abuse disorder prior to or during
the study period; prescription of more than one of
 
the study antidepressants on the index date; or sub-
ject age under 18. The analytic sample consists of
2030 patients who received a depression-related di-
agnosis, filled an initial antidepressant prescription
for fluoxetine, paroxetine, or sertraline, and met the
above criteria.
Pharmaceutical treatment for a depressive ill-
ness may generally be characterized by three pro-
cesses and associated outcomes. First is the choice
of the initial antidepressant; second is the realiza-
tion of decisions by patients and providers that de-
termine the use of the antidepressant; and third is
the accumulation of total direct health care expen-
ditures associated with decisions made regarding
health care utilization.
These processes may be represented by the fol-
lowing system of equations:
(1a) 
(1b) 
(2) 
(3a) 
(3b) 
(3c) 
where:
D is the indicator for initial antidepressant selec-
tion with fluoxetine the reference category:
D
 
s
 
 
 

 
 1 if sertraline, D
 
s
 
 
 

 
 0 if fluoxetine;
D
 
p
 
 
 

 
 1 if paroxetine; D
 
p
 
 
 

 
 0 if fluoxetine;
A is the indicator for minimal guideline adherence:
A 
 

 
 1 if patient filled at least four antidepressant
prescriptions in the 6 months following initia-
tion of therapy;
A 
 

 
 0 if otherwise;
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 are the 2-year direct health care expen-
ditures associated with use of fluoxetine, par-
oxetine or sertraline, respectively;
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are parameters to be estimated;
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, i 
 

 
 1, 2, 3, 4, 5, 6 are error terms.
Drug selection occurs first in this sequence of
events. Antidepressant Drug Choice 
 
(D)
 
 indicator
variables are defined to show receipt of fluoxetine,
paroxetine, or sertraline. Implementation of the
model is carried out employing fluoxetine as the
Ds X1β1 ε1+=
Dp X1β2 ε2+=
A X2β3 Dpπ p Dsπs ε3+++=
CF X3βF AθF ΓFγF ε4+++=
Cp X3βp Aθp Γpγp ε5+++=
Cs X3βs Aθs Γsγ s ε6+++=
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reference category. We began by estimating a mul-
tinomial logit (MNL) model of treatment selection
(Equation 1). MNL models are widely used to
estimate equations having discrete, nonordinal-
dependent variables. The explanatory variables in
the model included patient demographic charac-
teristics, depression diagnosis, and controls for
disease severity and provider type, which were hy-
pothesized a priori to be important determinants
of the outcomes. In addition, the variable Mean
Number of Months to the Index Date was in-
cluded to control for the different lengths of time
the three antidepressants had been available on
the market at the time of the study. All the above
are captured in the term X
 
1
 
.
The choice of MNL as the initial estimation
strategy for Equation 1 was also motivated by the
possibility of applying Lee’s [21] strategy for es-
timating Heckman-style sample selection models
that involve more than two choices. In brief, the
Lee approach involves the substitution of the pre-
dicted latent indexes from the MNL into the stan-
dard normal distribution. Estimation of the sam-
ple selection models then proceeds in the standard
fashion, assuming a bivariate normal distribution
between the transformed residuals of the MNL
and the regression model of interest. This ap-
proach was used to test for the presence of selec-
tion bias in the expenditure equations for the pa-
tients treated with each of the SSRIs.
Subsequent to the choice of antidepressant, the
patient’s use of the medication occurs and health
care expenditures are incurred. Guideline Adher-
ence (A) is defined as a two-category variable that
is equal to 1 if the patient received at least four an-
tidepressant prescriptions within the first 6 months
after beginning therapy and 0 otherwise. The former
category is referred to as the guideline adherent
cohort. The likelihood of patients adhering to de-
pression-treatment guidelines differs among the
SSRIs [22]. There are often gaps in prescription re-
fill patterns in prescription claims databases. These
gaps occur because of variability introduced when
patients actually refill their prescriptions and sub-
mit the necessary claims. Consequently, receipt of
four prescriptions within the first 6 months of ini-
tiating antidepressant therapy is considered to be
a conservative estimate of continuous antidepres-
sant use in light of Agency for Health Care Policy
and Research (AHCPR) recommended treatment
guidelines [2]. Equation 2, reflecting factors that
influence guideline adherence, is estimated using a
binary probit specification. Initially, this model is
estimated using all observations and it includes in-
dicator variables for treatments with sertraline and
paroxetine (with fluoxetine as the reference cate-
gory) as explanatory variables.
Health care expenditures (C) are defined as the
natural logarithm of total direct reimbursed health
care payments incurred during the 2-year study
period. The raw amounts were first adjusted to
1996 dollars using the medical component of the
Consumer Price Index. Log-transformed payments
are used in the analysis because payments were
highly skewed; the log-transformed values more
closely approximate a normal distribution. Service
components included in total expenditures for each
patient are: hospitalizations, emergency room vis-
its, laboratory resources, physician visits, other out-
patient ancillary services, study antidepressant and
other psychotropic prescriptions, and other pre-
scriptions. These expenditure categories represent
the accumulation of individual encounters with
the health care system over the course of each per-
son’s 2-year follow-up period as represented in the
MarketScan claims. All claims for individuals in-
cluded in the study were fully adjudicated as part
of the database construction process. Similarly,
health care utilization by patients under mental
health carve-outs was included in MarketScan when
the database was constructed. However, there was
not sufficient data to control for plan-level effects
on expenditures (such as negotiated reimbursement
rates for certain types of services). Nor was it pos-
sible to control for physician-level effects such as
prescribing preferences. It is partly because of these
omitted variables that considerable attention is given
to alternative methods of testing for sample selec-
tion bias and other specification issues. Control
variables were included in the statistical analysis
to adjust for provider type and geographical dif-
ferences.
The expenditure equation (Equation 3) includes
inverse Mills ratios as controls for possible sample
selection bias. Initial tests focused on sample-selec-
tion bias due to unobservable variables correlated
with both antidepressant selection and expendi-
tures [23,24]. However, before drawing inferences
about the presence or absence of selection bias, we
investigated the extent to which the inverse Mills
ratios were correlated with the other explanatory
variables in the expenditure equation. This was
done to evaluate the possibility that multicolline-
arity between the inverse Mills ratio and the other
explanatory variables might inflate the standard
errors of the parameter estimates and thereby un-
derstate the true level of statistical significance re-
garding treatment selection bias in the expenditure
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equation. On the other hand, if there is no direct
evidence of sample selection bias (i.e., the inverse
Mills ratios are statistically insignificant in the ex-
penditure regression) nor a strong correlation be-
tween the inverse Mills ratios and the other ex-
planatory variables in the expenditure equations,
then estimation of the expenditure equations by
ordinary least squares (OLS) may be appropriate.
Additional specification testing focused on: 1)
the relationship between treatment selection and
guideline adherence (Equations 1 and 2); 2) the re-
lation between guideline adherence and expendi-
tures (Equations 2 and 3); 3) the influence of in-
cluding depression diagnoses other than MDD;
and 4) the possibility that heteroscedasticity may
be affecting results from estimation of the expen-
diture equations. To assess the degree of covari-
ance between the drug selection and guideline ad-
herence equations, bivariate probit sample selection
models for sertraline relative to fluoxetine and for
paroxetine relative to fluoxetine were estimated. In
these bivariate probit selection models, the equa-
tions for drug choice, guideline adherence, and ex-
penditures were jointly estimated. The model also
allowed tests of sample selectivity bias stemming
from unobserved variables in treatment selection,
guideline adherence, or both, that are also corre-
lated with expenditures. Based on these findings,
expenditure equations with controls for selection
bias caused by unobservable factors that are cor-
related with both guideline adherence and expen-
ditures were also estimated. To examine the ro-
bustness of results to the inclusion of a wide range
of depression diagnoses categories, a reanalysis
of the data limited to MDD patients was under-
taken. Finally, the expenditure equation was esti-
mated using White’s correction for heteroscedas-
ticity [24].
In summary, proper estimation of the model
hinges on the nature of the interrelationships among
the equations, which are reflected in the covari-
ance among their error terms. We investigated a
wide variety of alternative specifications to evaluate
the robustness of findings under different modeling
approaches. Initially, we assume zero covariance
between treatment choice and guideline adherence,
zero covariance between guideline adherence and
expenditures, and a bivariate normal covariance
between the retransformed errors from the MNL
treatment choice equation and each of the residu-
als of the expenditure equations [21–27]. This ini-
tial specification is then subjected to a variety of
specification tests eventually resulting in a some-
what different specification that involves correc-
tion for sample selection by guideline adherence
but not for treatment selection.
Data management and statistical analyses were
conducted using the SAS and Limdep statistical pack-
ages (The SAS Institute, Cary, NC; WH Greene, New
York, NY). The 5% (two-tailed) significance level
was used for statistical tests.
 
Results
 
The sample consisted of 882 patients who were
initially prescribed fluoxetine as their antidepres-
sant therapy, 796 patients who began with sertra-
line, and 352 who began with paroxetine (Table
1). The average age of fluoxetine patients (41.3
years) was slightly below that of sertraline patients
(42.8 years) and paroxetine patients (43.0 years).
The percentage of MDD single episode was high-
est for sertraline patients (22.4%) compared to
paroxetine (20.2%) and fluoxetine patients (16.2%).
However, the percentage of MDD recurrent epi-
sodes was highest for paroxetine patients (17.0%),
followed by fluoxetine (13.1%) and sertraline pa-
tients (10.2%). The percentages of the remaining
depression diagnoses did not differ statistically
across the treatment cohorts. The paroxetine co-
hort had the highest proportion of patients with
prior anxiolytic use (23.3%), followed by the ser-
traline cohort (22.5%) and finally, the fluoxetine
treatment group (16.9%). The mean numbers of
non-mental illnesses were 6.2 for fluoxetine pa-
tients, 6.5 for sertraline patients, and 6.2 for par-
oxetine. The mean Number of Months to Index
Date was 24.7 for fluoxetine patients, 25.7 for ser-
traline patients, and 26.2 for paroxetine patients.
Finally, 57% of the fluoxetine cohort achieved an
antidepressant use pattern that was minimally ad-
herent with treatment guidelines. This compared to
48% of the sertraline-treated patients and 48.6%
of paroxetine-treated patients.
The unadjusted, 2-year direct health care expendi-
tures for the three treatment groups are shown in
Table 2. There was no statistically significant differ-
ence in the average total health care expenditures
across the treatment cohorts. Similarly, there were
no significant differences in average expenditures for
the 2-year depression-related, mental health, other
mental health, and non-mental health cost compo-
nents. Only average drug acquisition costs showed
statistical differences across the cohorts, although
this result did not carry through to the total health
care expenditures.
Table 3 reports results from the MNL model
for initial antidepressant selection (Equation 1).
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Factors with a statistically significant positive
probability of being prescribed sertraline relative
to fluoxetine included: the patient’s age, a diagno-
sis of MDD single episode, history of at least one
anxiolytic or sedative-hypnotic prescription in the
prior period, and a depression episode that started
later in the study period. Similarly, age, receipt of
at least one anxiolytic or sedative-hypnotic pre-
scription in the prior period, and history of a de-
pressive episode that started later in the study pe-
riod were also statistically significant and positively
associated with being prescribed paroxetine relative
to fluoxetine.
Results of analysis of the factors associated
with achieving guideline-adherent antidepressant
use are shown in Table 4. Older age, female gen-
der, and domicile in the north central region of the
United States were factors associated with having
a statistically significant higher probability of fill-
ing at least four prescriptions within the first 6
months following the index date. A diagnosis of
MDD single or recurrent episodes, neurotic de-
pression, a procedure code for psychotherapy, a
higher number of comorbid non-mental illnesses,
a family practitioner as the provider, and initial
 
prescriptions for sertraline or paroxetine (versus
fluoxetine) were all factors that significantly re-
duced the statistical probability that patients would
be guideline adherent.
Table 5 presents estimates from the initial
treatment choice sample selection models of total
2-year expenditures for each of the treatment co-
horts. For all three therapies, patients with a
higher number of non-mental illnesses had signifi-
cantly greater health care expenditures. Also, guide-
line adherence was associated with significantly lower
costs across the treatment categories. In the fluoxetine
cohort, age was positively and significantly associ-
 
Table 1
 
Descriptive statistics
 
Variable
Fluoxetine 
(N 
 

 
 882)
Sertraline 
(N 
 

 
 796)
Paroxetine 
(N  352) P-value
Patient demographics
Mean Age (years) 41.35 42.84 42.97 .005
% Female 67.99 71.23 67.90 .298
% North Central Region 91.72 90.95 89.20 .378
Depression indicator variables
% MDD-single episode 16.21 22.36 20.17 .006
% MDD-recurrent episode 13.15 10.18 17.05 .005
% Neurotic depression 29.82 26.26 26.42 .216
% Brief depressive reaction 6.69 7.41 5.40 .454
% Prolonged depressive reaction 0.57 1.13 1.14 .404
% Depressive disorder NEC 33.56 32.66 29.83 .450
Disease severity variables
% Anxiety/reaction to stress 27.32 26.63 22.44 .200
% Non-psych. admission in prior period 3.40 3.52 4.55 .607
% Anxiolytic in prior period 16.89 22.49 23.30 .005
% 20–30 minute psychotherapy session 28.12 28.39 30.11 .775
% 45–50 minute psychotherapy session 55.56 51.88 50.85 .193
Mean number of MDCs in prior period 3.42 3.43 3.34 .796
Mean number of psychotherapy codes 0.75 0.65 0.69 .762
Mean number of non-mental illnesses 6.16 6.53 6.22 .042
Mean number of concomitant drugs 0.51 0.50 0.43 .173
Provider variables
% Family practitioner 31.07 30.28 29.55 .860
% Other HC Clin. (Non-specialist) 12.13 14.45 10.80 .169
% Other acute care clinic or PC setting 27.10 26.01 28.13 .738
% Psychiatrist/Psychologist 29.71 29.27 31.53 .736
Mean number of months to index date 12.74 13.67 14.24 .001
Drug use
% Guideline adherent 57.03 47.99 48.58 .001
NEC not elsewhere classified.
MDC major diagnostic codes.
HC healthcare.
PC primary care.
Table 2 Mean 2-year expenditures
Cost Category ($)
Fluoxetine 
N  882
Sertraline
N  796
Paroxetine 
N  352 P-value
Total health care 9,396.31 9,626.92 9,398.46 .929
Antidepressant drug 921.29 737.45 628.45 .000
Depression-related 1,468.17 1,507.07 1,581.72 .875
Mental health care 3,467.76 3,011.56 3,035.61 .190
Other mental 
health care 1,078.30 767.04 825.49 .103
Non-mental health 
care 5,928.55 6615.35 6362.86 .494
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Table 3 Drug selection reference category is fluoxetine
Sertraline 
(N  1678)
Paroxetine 
(N  1234)
Variable Definition Coefficient t-statistic Coefficient t-statistic
Constant 1.262 3.523‡ 2.087 4.549‡
Demographics Age 0.013 2.744‡ 0.015 2.303‡
Female  1 0.196 1.763 0.068 0.484
Indicator: North Central Region 0.059 0.318 0.199 0.880
DDIV* MDD  single episode 0.390 2.491§ 0.344 1.686
MDD  recurrent episode 0.195 1.037 0.386 1.730
Neurotic depression 0.144 0.944 0.084 0.428
Brief depressive reaction 0.153 0.714 0.091 0.300
Prolonged depressive reaction 0.716 1.252 0.871 1.260
Other disease 
severity variables Prior non-psychiatric admission 0.046 0.167 0.369 1.130
Indicator: neurosis/reaction to stress 0.127 0.955 0.192 1.088
Prior period At least one anxiolytic or 
sedative-hypnotic prescription 0.277 2.141§ 0.329 2.020§
Number of psychotherapy visits 0.015 0.747 0.003 0.142
Number of body system diagnoses 0.018 0.757 0.033 1.079
Provider variables† Family practitioner 0.035 0.233 0.041 0.213
Other health care provider 0.057 0.323 0.392 1.623
Other/unknown provider 0.041 0.302 0.034 0.198
Other Months to index date 0.019 2.592 0.035 3.615‡
Model chi-square 71.893
*Depression Disease Indicator Variables: Omitted category is depression not elsewhere specified.
†Omitted category is psychiatrist.
‡ , § ,  Statistically significant at P  .001, .05, and .01 levels, respectively.
MDD, major depressive disorder.
Table 4 Use pattern estimation—guideline adherent use pattern  1 (N  2030)
Variable Definition Coefficient t-statistic
Constant 0.065 0.310
Patient demographics Age 0.008 2.868
Female  1 0.183 2.831
Indicator: North Central Region 0.320 3.046
DDIV* MDD single episode 0.200 2.228§
MDD recurrent episode 0.283 2.681
Neurotic depression 0.200 2.284§
Brief depressive reaction 0.133 1.062
Prolonged depressive reaction 0.019 0.062
Other disease 
severity variables
Prior non-psychiatric admission 0.078 0.519
Indicator: neurosis/reaction to stress 0.015 0.204
Prior period Had at least 1 anxiolytic or 
sedative-hypnotic prescription 0.069 0.957
Number of psychotherapy visits 0.004 0.373
Study period 20–30 minute psychotherapy 
session (Code 90843) 0.121 1.797
45–50 minute psychotherapy 
session (Code 90844) 0.201 3.270
Number of non-mental illnesses 0.024 2.382§
Provider variables† Family practitioner 0.191 2.173§
Other health care provider 0.102 0.989
Other/unknown provider 0.101 1.300
Other variables Months to index date 0.002 0.458
Patient index drug—Sertraline 0.246 3.906‡
Patient index drug—Paroxetine 0.218 2.700
Model chi-square 79.887
*Depression Disease Indicator Variables: Omitted category is depression not elsewhere specified.
†Omitted category is psychiatrist.
‡ , § ,  Statistically significant at P  .001, .05, and .01 levels, respectively.
MDD, major depressive disorder.
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ated with greater cost. Expenditures in the parox-
etine regression were significantly reduced by a di-
agnosis of neurotic depression and by receipt of
the initial prescription from a family practitioner.
These estimates were carried out including sample
selection terms calculated from a generalized se-
lectivity model that allowed examination of the
possibility of correlation between the initial selec-
tion from among SSRI antidepressants and cost
outcomes [21]. However, the inverse Mills ratios
were not statistically significant in the sample se-
lection regressions for health care expenditures,
suggesting that selectivity bias stemming from an-
tidepressant drug choice was not a problem.
Before accepting the above conclusion regard-
ing the absence of selectivity bias, however, we
tested for the possibility that multicollinearity might
be inflating the standard errors of the inverse Mills
ratio parameter estimates. The coefficient of multi-
ple determination (R2) values from regressions of
the inverse Mills ratios on other explanatory vari-
ables from the expenditure equations were: 0.33
for the fluoxetine equation; 0.83 for the sertraline
regression; and 0.31 for the paroxetine regression.
The R2 for sertraline was of sufficient magnitude
to raise concern about the possibility that multi-
collinearity may have obscured the presence of
sample selection bias by artificially inflating the
standard errors. However, when the magnitudes
and statistical significance of the parameter esti-
mates were compared to OLS estimates, they were
found to be very similar. On balance, the evidence
does not seem to indicate the presence of selectiv-
ity bias in expenditure outcomes associated with
drug selection. We now turn to alternative specifi-
cation tests.
The results presented in Tables 3, 4, and 5 did
not account for covariance between the trans-
formed residuals of the MNL drug selection equa-
tion and the residuals of the guideline adherence
equation, nor between the residuals of the adher-
ence and expenditure equations. The Lee model
did account for the covariance between drug selec-
tion and expenditures. To further investigate the
correctness of this specification, two bivariate pro-
bit models were estimated that closely mirrored
the specifications discussed thus far.
The first model investigated the bivariate selec-
tion of sertraline versus fluoxetine with guideline
adherence. The signs and statistical significance of
the parameter estimates in the drug selection pro-
bit portion of the model were identical to those of
Table 5 Total 2-year expenditures—treatment selection models
Variable Definition
Fluoxetine model 
(N  882)
Sertraline model 
(N  796)
Paroxetine model 
(N  352)
Coefficient t-statistic Coefficient t-statistic Coefficient t-statistic
Constant 8.377 16.079‡ 9.665 5.435‡ 9.741 7.659‡
Patient demographics Age 0.023 3.386‡ 0.010 1.132 0.002 0.243
Female  1 0.243 1.908 0.034 0.195 0.081 0.596
Indicator: North Central Region 0.239 1.158 0.371 1.554 0.071 0.329
DDIV* MDD  single episode 0.088 0.425 0.112 0.429 0.360 1.897
MDD  recurrent episode 0.033 0.166 0.026 0.086 0.282 1.076
Neurotic depression 0.081 0.496 0.211 0.987 0.573 2.871
Brief depressive reaction 0.057 0.242 0.381 1.286 0.101 0.355
Prolonged depressive reaction 0.184 0.248 0.375 0.561 0.448 0.736
Disease severity variables Prior non-psychiatric admission 0.002 0.007 0.648 1.880 0.488 1.606
Indicator: neurosis/ reaction 
to stress 0.035 0.249 0.093 0.489 0.217 1.159
During study period 20–30 minute psychotherapy 
session 90843 0.001 0.009 0.265 1.796 0.161 1.100
45–50 minute psychotherapy 
session 90844 0.111 0.964 0.105 0.781 0.256 1.920
Number of non-mental illnesses 0.172 8.751‡ 0.143 6.399‡ 0.138 6.268‡
Number of concomitant drugs 
taken period 0.057 0.706 0.145 1.531 0.117 1.293
Provider variables† Family practitioner 0.163 0.974 0.228 1.163 0.380 2.085§
Other health care provider 0.059 0.304 0.059 0.232 0.127 0.501
Other/unknown provider 0.041 0.276 0.045 0.258 0.220 1.372
Other variables Guideline Adherent use pattern 2.772 25.377‡ 3.058 24.257‡ 1.577 13.034‡
Adjustment factor for
self-selection 0.598 0.945 1.350 0.987 0.771 0.996
*Depression Disease Indicator Variables: Omitted category is depression not elsewhere specified.
†Omitted category is psychiatrist.
‡ , § ,  Statistically significant at P  .001, .05, and .01 levels, respectively.
MDD, major depressive disorder.
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the parameters reported in Table 3 for the sertra-
line/fluoxetine comparison. Similarly, the signs and
statistical significance of the parameter estimates
from the drug selection portion of the bivariate
probit selection model of paroxetine versus fluox-
etine were identical to the MNL results reported
in Table 3. This suggests that the effect of jointly
estimating the drug selection and guideline adher-
ence equations had little impact on the signs or
statistical significance of the drug selection param-
eters. The correlation coefficients between the re-
siduals from the drug selection and guideline ad-
herence equations estimated in the bivariate probit
models were 0.16 for sertraline/fluoxetine and
0.12 for paroxetine/fluoxetine.
A second important finding from the bivariate
probit selection models was that no evidence of se-
lection bias by treatment was observed in any of
the four expenditure equations for the drug co-
hort/guideline adherent subsamples estimated for
either model. This result was consistent with the
results from the Lee model [21]. However, there
was evidence of selection bias by guideline-adher-
ent status in several of the expenditure equations
estimated for the drug cohort/adherent status sub-
groups. As a consequence, the expenditure equa-
tions for each treatment cohort were estimated
controlling for possible selection bias from treat-
ment compliance.
The expenditure models controlling for selec-
tion bias from guideline adherence are reported in
Table 6. Common findings across the treatments
from the guideline-adherent selection models were
that psychotherapy visits (CPT codes 90843 and
90844) and number of non-mental illnesses were
positively and statistically significantly associated
with total expenditures. For the fluoxetine and
sertraline cohorts, age, concomitant medications,
and unobservable variables correlated with the
guideline-adherent use pattern had a positive, sta-
tistically significant relation to total expenditures.
A prior nonpsychiatric admission was statistically
significantly associated with higher expenditures
for the sertraline and paroxetine cohorts, but not
for the fluoxetine cohort. Diagnosis of MDD sin-
gle or recurrent episode and neurotic depression
were positively and statistically significantly re-
lated to total expenditures for the fluoxetine co-
hort. In the sertraline cohort, an indicator for
neurosis/stress was positively related to total ex-
penditures, whereas the indicator for gender showed
females tended to have lower expenditures than oth-
erwise similar males. As noted above, some evidence
of selectivity bias from unobserved variables corre-
lated with both guideline adherence and expendi-
tures was found. The inverse Mills ratios were posi-
tive and statistically significant in both the fluoxetine
and sertraline equations.
Table 6 Total 2-year expenditures—drug adherence selection models
Fluoxetine (N  882) Sertraline (N  796) Paroxetine (N  352)
Variable Definition Coeffiecient t-statistic Coefficient t-statistic Coefficient t-statistic
Constant 6.916 42.946‡ 7.053 37.652‡ 7.063 24.480‡
Patient demographics Age 0.006 2.602 0.007 2.670 0.007 1.640
Female  1 0.021 0.385 0.212 3.349‡ 0.041 0.435
Indicator: North Central Region 0.085 0.905 0.094 0.931 0.008 0.058
DDIV* MDD  single episode 0.155 1.889 0.104 1.238 0.035 0.283
MDD  recurrent episode 0.203 2.235§ 0.167 1.534 0.133 0.956
Neurotic depression 0.180 2.426§ 0.033 0.384 0.204 1.563
Brief depressive reaction 0.081 0.747 0.021 0.182 0.075 0.383
Prolonged depressive reaction 0.459 1.392 0.223 0.836 0.041 0.101
Other disease 
severity variables
Prior non-psychiatric admission 0.252 1.862 0.734 4.906‡ 0.421 2.126§
Indicator: neurosis/reaction to stress 0.052 0.825 0.214 2.966 0.160 1.365
Study period 20–30 minute psychotherapy (90843) 0.263 4.470‡ 0.224 3.432‡ 0.268 2.677
45–50 minute psychotherapy (90844) 0.294 5.535‡ 0.380 6.448‡ 0.347 3.767‡
Number of non-mental illnesses 0.178 19.853‡ 0.175 17.943‡ 0.167 11.290‡
Number of concomitant drugs 0.136 3.635‡ 0.098 2.356§ 0.117 1.878
Provider variables† Family practitioner 0.098 1.278 0.117 1.365 0.188 1.507
Other health care provider 0.068 0.757 0.088 0.917 0.069 0.433
Other/unknown provider 0.070 1.033 0.008 0.105 0.056 0.507
Selection Term Inverse Mills Ratio 0.070 2.260§ 0.085 2.471§ 0.042 0.819
Mean (SD) dependent variable 8.679 (0.969) 8.677 (1.018) 8.619 (0.981)
Adjusted R2 0.445 0.436 0.400
*Depression Disease Indicator Variables: Omitted category is depression not elsewhere specified.
†Omitted category is psychiatrist.
‡ , § ,  Statistically significant at P  .001, .05, and .01 levels, respectively.
MDD, major depressive disorder.
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It is interesting to note that, with one excep-
tion, the signs and statistical significance of the
parameter estimates reported in Table 6 are identi-
cal to their OLS counterparts containing a dummy
variable for guideline adherence (not reported
here); specifically, the parameter estimate for MDD
single episode, which was significant in the OLS
model for the fluoxetine cohort, slips just below
the .05 significance level in the guideline adherent
selection model. It may be that the inverse Mills
ratio for guideline adherence is acting like an in-
strumental variable; hence, the high correlation be-
tween the dummy variable and the inverse Mills ratio
for guideline adherence. However, we chose to re-
port the guideline selection models as the final
specification because of the evidence of selection
bias from the bivariate probit selection models.
Pairwise comparisons of total 2-year direct
health care expenditures for fluoxetine, sertraline,
and paroxetine patients were conducted based
upon the above estimates. Statistically significant
differences among the SSRIs were not detected in
any of the pairwise total cost comparisons across
the three treatments. These findings paralleled
those of the descriptive results presented in Table
2. Alternatively, in a pooled model of expendi-
tures with dummy variables included for sertraline
and paroxetine, the parameter estimates for ser-
traline and paroxetine treatments were statistically
insignificant. Finally, an analysis with the sample
restricted to only those patients with a diagnosis
of MDD revealed similar results.
OLS versions of the total expenditure models
were tested for the presence of heteroscedasticity
using White’s test [24]. There were no changes in
signs or statistical significance of any of the pa-
rameter estimates relative to the guideline-adher-
ent selection models. Also, an assessment of the
joint determination of guideline-adherent use and
expenditures was undertaken. The Hausman test
statistics for the three treatments (fluoxetine 2.09,
sertraline 0.56, and paroxetine 0.25) were all well
below the critical value of 28.87, and thus this test
failed to reject the null hypothesis of no endogene-
ity between guideline adherence and health care
expenditures. Taken together, the specification test-
ing with respect to selection bias from treatment
choice, or from guideline adherence, and the insen-
sitivity of the results to heteroscedasticity support
the guideline-adherent sample-selection models as
the appropriate specification. The general model
remains as written above (Equations 1–3) where
all terms are defined as before except that i (i 
F, P, or S) now refer to the inverse Mills ratio for
guideline adherence. This model assumes a bivari-
ate normal covariance between the residuals of the
guideline adherent equation (Equation 2) and each
of the expenditure equations (3a–3c). All other co-
variances among the residuals across equations
are assumed to be zero.
Detailed multivariate modeling was conducted
only on total 2-year expenditures. This reflects the
decision to adopt the broadest possible cost mea-
sure consistent with the perspective of the study.
Nevertheless, it is apparent from the OLS findings
reported in Table 7 that significant statistical dif-
ferences did emerge when subcomponents of di-
rect health care expenditures were analyzed. Both
Table 7 Comparison of total 2-year expenditures—predicted log values (SE) from OLS models
Fluoxetine 
N  882
Sertraline 
N  796
Paroxetine 
N  352
Total health care expenditures (SE)
vs. Fluoxetine 8.700 8.650 (0.037) 8.636 (0.050)
vs. Sertraline 8.636 (0.051)
Total mental health care expenditures
vs. Fluoxetine 7.489 7.342 (0.049)* 7.379 (0.062)
vs. Sertraline 7.379 (0.064)
Antidepressant drug expenditures
vs. Fluoxetine 6.264 6.052 (0.050)* 5.985 (0.064)*
vs. Sertraline 5.985 (0.066)
Depression-related expenditures
vs. Fluoxetine 5.776 5.662 (0.092) 5.777 (0.116)
vs. Sertraline 5.777 (0.119)
Other mental health care expenditures
vs. Fluoxetine 4.161 4.001 (0.138) 4.147 (0.178)
vs. Sertraline 4.147 (0.179)
Non-mental health care expenditures
vs. Fluoxetine 7.898 7.880 (0.055) 7.860 (0.068)
vs. Sertraline 7.860 (0.068)
*Statistically significant at P  .01.
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sertraline and paroxetine patients had lower 2-year
antidepressant acquisition costs than did fluoxet-
ine patients. Sertraline patients were found to have
lower 2-year mental health expenditures than flu-
oxetine patients. However, there were no statisti-
cally significant differences among the SSRIs in
2-year depression-related expenditures, other men-
tal health expenditures, or non-mental health ex-
penditures. No statistically significant differences
were detected between 2-year expenditures for any
of the cost measures among sertraline and paroxet-
ine patients.
Discussion
This study extends earlier retrospective research
using administrative claims databases by examin-
ing direct health care expenditures incurred during
an episode of care for depressive disorder over a
2-year period. There are two substantive conclu-
sions. First, relative to beginning treatment with
either sertraline or paroxetine, initial prescribing
of fluoxetine was associated with a higher likeli-
hood of patients achieving an antidepressant use
pattern that was minimally consistent with con-
sensus treatment guidelines (2, 6). Second, under
the broadest measure of health care utilization
considered in this paper (i.e., 2-year total health
care expenditures associated with a depressive dis-
order), there were no statistically significant dif-
ferences in total expenditures among the SSRI co-
horts. Statistically significant differences between
the treatment cohorts were found in more nar-
rowly defined subcomponents of health care ex-
penditures such as antidepressant acquisition costs.
Part of the explanation for the difference in an-
tidepressant expenditures for both sertraline and
paroxetine relative to fluoxetine may be the ob-
served differences in drug-use patterns. Although
clinical trials have concluded that available SSRIs
have similar efficacy, use of SSRIs in actual clini-
cal practice may differ because of pharmacological
differences in side effects or half-lives [28], discon-
tinuation symptomatology [29–31], or other fac-
tors. Compared to depression-diagnosed individu-
als who initiated therapy with fluoxetine, patients
who began therapy with sertraline or paroxetine
were found to be significantly less likely to receive
at least four antidepressant prescriptions in the en-
suing 6 months. The differences among the SSRIs
in the duration of antidepressant use observed in
this study are consistent with results from other
database analyses reflecting outcomes from clini-
cal practice [10,11,16,19,32,33]. The early dis-
continuation of treatment that was more likely to
be associated with initial prescribing of sertraline
and paroxetine therefore would be expected to
translate into lower antidepressant costs because
of the lower refill rate. However, not utilizing the
medications in a manner at least minimally adher-
ent with treatment guidelines increases the likeli-
hood of a recurrent episode of depression [3,34,35]
and may be associated with higher costs later on.
The econometric specification was designed to
test a model of antidepressant selection, adherence
to treatment guidelines, and total direct health
care expenditures. A key issue was the need to
carry out extensive specification testing to deter-
mine how well the model performed given the
types of biases that may affect results derived from
retrospective database analysis. The impact and
significance of bias in a database study is ulti-
mately an empirical issue. At a minimum, exten-
sive testing of the model is needed to guide the an-
alyst’s choice among alternative specifications.
In this study, there was no direct evidence that
selectivity bias due to treatment selection influ-
enced the estimate of total health care expendi-
tures. The beginning of the 1993-to-1996 study
period might have seen nonrandom initial antide-
pressant selection since paroxetine and sertraline
had been recently introduced to the market. The
Month to Index Date variable in the drug selec-
tion equations helped to account for increasing
physician experience with the newer pharmaceuti-
cals as time passed. However, the second sample
selection model showed that unobserved variables
correlated with both guideline adherence and
health care expenditures were statistically signifi-
cant factors influencing the expenditure equation
for the fluoxetine and sertraline cohorts. It might
be noted that there was a difference in signs be-
tween the parameter estimates for guideline adher-
ence in Table 5 (negative and significant) and the
parameter estimates for the inverse Mills ratios
(IMRs) for guideline compliance in Table 6 (posi-
tive and significant, except in the case of paroxe-
tine, which is not significant). Upon reflection, how-
ever, these two sets of results are consistent. The
parameter estimates for the IMRs represent the
amount of positive bias that would be introduced
by omitted variables that are correlated with
both guideline adherence and expenditures. In other
words, expected payments are lower after adjust-
ing for this source of selectivity bias. This is con-
sistent with the negative parameter estimates for
the guideline adherence dummy variables.
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Results from the other specification tests sup-
port the above results as the appropriate specifica-
tion. The White procedure for computing hetero-
scedasticity-robust standard errors revealed that
possible heteroscedasticity of the disturbances was
not influencing the conclusions. Berndt et al. [18]
also reported results from similar administrative
claims data that were not sensitive to heterosce-
dasticity. Also, restricting the analysis to patients
with a diagnosis of MDD did not alter the main
conclusion.
A limitation of the study was a lack of data on
the underlying clinical outcomes such as clinical
symptom scores. Thus, the findings of our study
cannot be used to directly assess the appropriate-
ness of the realized use pattern of these patients
from a clinical standpoint. However, other studies
have shown that reduced rates of relapse and re-
currence, reduced disability, and improved patient
functioning are associated with improvement in
quality of care [3,36,37]. It is also not possible to
know with certainty whether patients were taking
all their medications.
Further research to extend the analyses re-
ported here would consider other outcomes in ad-
dition to expenditures. For example, using the pa-
tient-level episodes of depression constructed for
this study, one might examine the effects of alter-
native therapies on the probability of depression
relapse, the time to depression relapse, or other
measures of service utilization such as the number
of subsequent outpatient visits or hospitalizations.
Also, future research might delve deeper into
treatment adherence using this framework. One
extension would be to a measure of guideline-ad-
herent antidepressant use that is beyond the defi-
nition of minimal adherence that is used here. For
instance, the impact of drug-use patterns such as
switching, augmentation, or titration might be ex-
amined. Finally, it may be possible to use the ob-
served patterns of prescription refills to construct
an estimate of therapeutic days achieved based
upon apparent daily dosing and to include this as
part of the model.
Antidepressant choice is important since better
quality of care is expected to lead to lower rates of
relapse and recurrence, reductions in disability,
and improvements in functioning. This study has
shown that, relative to treatment with paroxetine
or sertraline, initiation of antidepressant therapy
with fluoxetine was more likely to lead to antide-
pressant use in clinical practice that was minimally
consistent with prescribing guidelines. Further, this
better quality of care that was associated with ini-
tial prescribing of fluoxetine was achieved without
a statistically significant difference in total 2-year
expenditures incurred while treating a depressive
episode.
Partial funding for this research was provided by Eli Lilly
and Company.
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